Comparative Pharmacology
Head-to-head clinical analysis: NEO POLYCIN versus OPHTHOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO POLYCIN versus OPHTHOCORT.
NEO-POLYCIN vs OPHTHOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis. Polymyxin B is a polypeptide antibiotic that disrupts bacterial cell membrane permeability by interacting with phospholipids. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier.
OPHTHOCORT contains chloramphenicol, a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation; and hydrocortisone, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
Apply a thin layer to the affected area 3 to 4 times daily. Use a unit-dose ointment or eye drops: 1 to 2 drops in the affected eye(s) every 4 to 6 hours, or more frequently as needed.
One drop into the affected eye(s) every 3-4 hours, or more frequently as needed. In severe cases, one drop every hour. Shake well before use.
None Documented
None Documented
Neomycin: 2-3 hours in patients with normal renal function; prolonged to 12-24 hours in renal impairment. Polymyxin B: 6-8 hours. Bacitracin: 1.5 hours (if absorbed); typically not systemically available.
Terminal elimination half-life: 2.5-3.5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Neomycin: ~30-50% of absorbed dose excreted renally as unchanged drug; unabsorbed drug eliminated fecally. Polymyxin B: minimal renal excretion (<1% of dose); primarily eliminated via non-renal routes, possibly biliary or metabolic. Bacitracin: negligible renal excretion after topical use; systemic absorption minimal.
Renal (70-80% as unchanged drug), fecal (15-20% via biliary elimination), with minor metabolic clearance.
Category C
Category C
Antibiotic Combination
Ophthalmic Corticosteroid/Antibiotic Combination